191 related articles for article (PubMed ID: 38655783)
1. When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity.
Pan D; Wang Q; Shen A; Qi Z; Zheng C; Hu B
Int J Cancer; 2024 Aug; 155(3):384-399. PubMed ID: 38655783
[TBL] [Abstract][Full Text] [Related]
2. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.
Ye Z; Shi Y; Lees-Miller SP; Tainer JA
Front Immunol; 2021; 12():797880. PubMed ID: 34970273
[TBL] [Abstract][Full Text] [Related]
3. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
Front Immunol; 2022; 13():943090. PubMed ID: 36081518
[TBL] [Abstract][Full Text] [Related]
4. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
5. DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Reisländer T; Groelly FJ; Tarsounas M
Mol Cell; 2020 Oct; 80(1):21-28. PubMed ID: 32810436
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.
Clark CA; Yang ES
J Immunother Precis Oncol; 2023 Feb; 6(1):31-49. PubMed ID: 36751656
[TBL] [Abstract][Full Text] [Related]
7. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
9. Advances of DNA Damage Repair-Related Drugs and Combination With Immunotherapy in Tumor Treatment.
Wang Y; Duan M; Peng Z; Fan R; He Y; Zhang H; Xiong W; Jiang W
Front Immunol; 2022; 13():854730. PubMed ID: 35281059
[TBL] [Abstract][Full Text] [Related]
10. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
11. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
14. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
15. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
Lou S; Wang Y; Zhang J; Yin X; Zhang Y; Wang Y; Xue Y
Front Immunol; 2021; 12():806324. PubMed ID: 35082793
[TBL] [Abstract][Full Text] [Related]
16. Targeting the DNA damage response in immuno-oncology: developments and opportunities.
Chabanon RM; Rouanne M; Lord CJ; Soria JC; Pasero P; Postel-Vinay S
Nat Rev Cancer; 2021 Nov; 21(11):701-717. PubMed ID: 34376827
[TBL] [Abstract][Full Text] [Related]
17. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
18. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
19. Diverse immune response of DNA damage repair-deficient tumors.
Qing T; Jun T; Lindblad KE; Lujambio A; Marczyk M; Pusztai L; Huang KL
Cell Rep Med; 2021 May; 2(5):100276. PubMed ID: 34095878
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]